pSivida Corp. announced that Finland and Luxembourg have granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This brings the total number of EU countries in which ILUVIEN has been approved to 15, with two EU approvals still pending.